Switch-peptides

From conformational studies to Alzheimer's disease

Lydiane Saucède, Sonia Dos Santos, Arunan Chandravarkar, Bhubaneswar Mandal, Richard Mimna, Karine Murat, Marie Stéphanie Camus, Jérémy Bérard, Eric Grouzmann, Marc Adrian, Jacques Dubochet, John Lopez, Hilal Lashuel, Gabriele Tuchscherer, Manfred Mutter

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Studies on designed peptides that exhibit high tendencies for medium-induced conformational transitions have recently attracted much attention because structural changes are considered as molecular key processes in degenerative diseases. The experimental access to these events has been limited so far mainly due to the intrinsic tendency of the involved polypeptides for self-association and aggregation, e.g. amyloid β plaque formation, thought to be at the origin of Alzheimer's disease. We have developed a new concept termed 'switch-peptides' which allows the controlled onset of polypeptide folding and misfolding in vitro and in vivo, starting from a soluble, non-toxic precursor molecule. As a major feature, the folding process is initiated by enzyme-triggered N,O-acyl migrations restoring the native peptide backbone in situ. As the folding is set off in the moment of creating the bioactive molecule ('in statu nascendi', ISN), our concept allows for the first time the investigation of the early steps of protein misfolding as relevant in degenerative diseases, opening new perspectives for the rational design of therapeutically relevant compounds.

Original languageEnglish
Pages (from-to)199-202
Number of pages4
JournalChimia
Volume60
Issue number4
DOIs
Publication statusPublished - 16 May 2006
Externally publishedYes

Fingerprint

Alzheimer Disease
Switches
Peptides
Molecules
Amyloid Plaques
Amyloid
Agglomeration
Enzymes
Proteins

Keywords

  • Degenerative diseases
  • Induction of biological function
  • Protein misfolding
  • Rational drug design
  • Switch-peptides

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Saucède, L., Dos Santos, S., Chandravarkar, A., Mandal, B., Mimna, R., Murat, K., ... Mutter, M. (2006). Switch-peptides: From conformational studies to Alzheimer's disease. Chimia, 60(4), 199-202. https://doi.org/10.2533/000942906777674921

Switch-peptides : From conformational studies to Alzheimer's disease. / Saucède, Lydiane; Dos Santos, Sonia; Chandravarkar, Arunan; Mandal, Bhubaneswar; Mimna, Richard; Murat, Karine; Camus, Marie Stéphanie; Bérard, Jérémy; Grouzmann, Eric; Adrian, Marc; Dubochet, Jacques; Lopez, John; Lashuel, Hilal; Tuchscherer, Gabriele; Mutter, Manfred.

In: Chimia, Vol. 60, No. 4, 16.05.2006, p. 199-202.

Research output: Contribution to journalArticle

Saucède, L, Dos Santos, S, Chandravarkar, A, Mandal, B, Mimna, R, Murat, K, Camus, MS, Bérard, J, Grouzmann, E, Adrian, M, Dubochet, J, Lopez, J, Lashuel, H, Tuchscherer, G & Mutter, M 2006, 'Switch-peptides: From conformational studies to Alzheimer's disease', Chimia, vol. 60, no. 4, pp. 199-202. https://doi.org/10.2533/000942906777674921
Saucède L, Dos Santos S, Chandravarkar A, Mandal B, Mimna R, Murat K et al. Switch-peptides: From conformational studies to Alzheimer's disease. Chimia. 2006 May 16;60(4):199-202. https://doi.org/10.2533/000942906777674921
Saucède, Lydiane ; Dos Santos, Sonia ; Chandravarkar, Arunan ; Mandal, Bhubaneswar ; Mimna, Richard ; Murat, Karine ; Camus, Marie Stéphanie ; Bérard, Jérémy ; Grouzmann, Eric ; Adrian, Marc ; Dubochet, Jacques ; Lopez, John ; Lashuel, Hilal ; Tuchscherer, Gabriele ; Mutter, Manfred. / Switch-peptides : From conformational studies to Alzheimer's disease. In: Chimia. 2006 ; Vol. 60, No. 4. pp. 199-202.
@article{90cc3c9681bf4439b09e0b9cb7cba8ac,
title = "Switch-peptides: From conformational studies to Alzheimer's disease",
abstract = "Studies on designed peptides that exhibit high tendencies for medium-induced conformational transitions have recently attracted much attention because structural changes are considered as molecular key processes in degenerative diseases. The experimental access to these events has been limited so far mainly due to the intrinsic tendency of the involved polypeptides for self-association and aggregation, e.g. amyloid β plaque formation, thought to be at the origin of Alzheimer's disease. We have developed a new concept termed 'switch-peptides' which allows the controlled onset of polypeptide folding and misfolding in vitro and in vivo, starting from a soluble, non-toxic precursor molecule. As a major feature, the folding process is initiated by enzyme-triggered N,O-acyl migrations restoring the native peptide backbone in situ. As the folding is set off in the moment of creating the bioactive molecule ('in statu nascendi', ISN), our concept allows for the first time the investigation of the early steps of protein misfolding as relevant in degenerative diseases, opening new perspectives for the rational design of therapeutically relevant compounds.",
keywords = "Degenerative diseases, Induction of biological function, Protein misfolding, Rational drug design, Switch-peptides",
author = "Lydiane Sauc{\`e}de and {Dos Santos}, Sonia and Arunan Chandravarkar and Bhubaneswar Mandal and Richard Mimna and Karine Murat and Camus, {Marie St{\'e}phanie} and J{\'e}r{\'e}my B{\'e}rard and Eric Grouzmann and Marc Adrian and Jacques Dubochet and John Lopez and Hilal Lashuel and Gabriele Tuchscherer and Manfred Mutter",
year = "2006",
month = "5",
day = "16",
doi = "10.2533/000942906777674921",
language = "English",
volume = "60",
pages = "199--202",
journal = "Chimia",
issn = "0009-4293",
publisher = "Swiss Chemical Society",
number = "4",

}

TY - JOUR

T1 - Switch-peptides

T2 - From conformational studies to Alzheimer's disease

AU - Saucède, Lydiane

AU - Dos Santos, Sonia

AU - Chandravarkar, Arunan

AU - Mandal, Bhubaneswar

AU - Mimna, Richard

AU - Murat, Karine

AU - Camus, Marie Stéphanie

AU - Bérard, Jérémy

AU - Grouzmann, Eric

AU - Adrian, Marc

AU - Dubochet, Jacques

AU - Lopez, John

AU - Lashuel, Hilal

AU - Tuchscherer, Gabriele

AU - Mutter, Manfred

PY - 2006/5/16

Y1 - 2006/5/16

N2 - Studies on designed peptides that exhibit high tendencies for medium-induced conformational transitions have recently attracted much attention because structural changes are considered as molecular key processes in degenerative diseases. The experimental access to these events has been limited so far mainly due to the intrinsic tendency of the involved polypeptides for self-association and aggregation, e.g. amyloid β plaque formation, thought to be at the origin of Alzheimer's disease. We have developed a new concept termed 'switch-peptides' which allows the controlled onset of polypeptide folding and misfolding in vitro and in vivo, starting from a soluble, non-toxic precursor molecule. As a major feature, the folding process is initiated by enzyme-triggered N,O-acyl migrations restoring the native peptide backbone in situ. As the folding is set off in the moment of creating the bioactive molecule ('in statu nascendi', ISN), our concept allows for the first time the investigation of the early steps of protein misfolding as relevant in degenerative diseases, opening new perspectives for the rational design of therapeutically relevant compounds.

AB - Studies on designed peptides that exhibit high tendencies for medium-induced conformational transitions have recently attracted much attention because structural changes are considered as molecular key processes in degenerative diseases. The experimental access to these events has been limited so far mainly due to the intrinsic tendency of the involved polypeptides for self-association and aggregation, e.g. amyloid β plaque formation, thought to be at the origin of Alzheimer's disease. We have developed a new concept termed 'switch-peptides' which allows the controlled onset of polypeptide folding and misfolding in vitro and in vivo, starting from a soluble, non-toxic precursor molecule. As a major feature, the folding process is initiated by enzyme-triggered N,O-acyl migrations restoring the native peptide backbone in situ. As the folding is set off in the moment of creating the bioactive molecule ('in statu nascendi', ISN), our concept allows for the first time the investigation of the early steps of protein misfolding as relevant in degenerative diseases, opening new perspectives for the rational design of therapeutically relevant compounds.

KW - Degenerative diseases

KW - Induction of biological function

KW - Protein misfolding

KW - Rational drug design

KW - Switch-peptides

UR - http://www.scopus.com/inward/record.url?scp=33646441371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646441371&partnerID=8YFLogxK

U2 - 10.2533/000942906777674921

DO - 10.2533/000942906777674921

M3 - Article

VL - 60

SP - 199

EP - 202

JO - Chimia

JF - Chimia

SN - 0009-4293

IS - 4

ER -